COPD Treatment: New Study & Hopeful Results
- Chronic Obstructive Pulmonary Disease (COPD) affects an estimated 600 million people worldwide, with only half aware they have it. The condition, characterized by shortness of breath, persistent cough,...
- However, a recent study conducted by the university of Copenhagen and Bispebjerg Hospital indicates that vitamin B3, specifically nicotinamide riboside, could improve the quality of life for those...
- Morten Scheibye-knudsen, an associate professor at the University of Copenhagen and co-author of the study, said nicotinamide riboside, also known as vitamin B3, can reduce lung inflammation in...
Vitamin B3 shows promise in the fight against Chronic Obstructive Pulmonary Disease (COPD)! A recent study reveals that nicotinamide riboside (vitamin B3) may reduce lung inflammation in COPD patients, potentially improving their quality of life. Participants in the study experienced a significant drop in inflammation markers, offering a glimmer of hope for those living with this challenging condition. COPD impacts millions globally, so this research into Vitamin B3 is welcome news. Results show a 53% reduction in IL-8 after six weeks, and 63% by 12 weeks! The study also found that vitamin B3 may increase NAD levels, which are often low in COPD patients. Discover more from this latest research via News Directory 3. Further studies are on the horizon to explore the long-term effects of this exciting development. Discover what’s next …
Vitamin B3 May Reduce Lung Inflammation in COPD Patients
Updated June 27, 2025
Chronic Obstructive Pulmonary Disease (COPD) affects an estimated 600 million people worldwide, with only half aware they have it. The condition, characterized by shortness of breath, persistent cough, wheezing, and frequent respiratory infections, significantly impacts daily life.
However, a recent study conducted by the university of Copenhagen and Bispebjerg Hospital indicates that vitamin B3, specifically nicotinamide riboside, could improve the quality of life for those with COPD by targeting lung inflammation, a key factor in reduced lung function.
Morten Scheibye-knudsen, an associate professor at the University of Copenhagen and co-author of the study, said nicotinamide riboside, also known as vitamin B3, can reduce lung inflammation in COPD patients. He added that inflammation can led to reduced lung function in these patients.
The double-blind study involved 40 COPD patients and 20 healthy individuals. Participants received either a placebo or two grams of vitamin B3 daily.After six weeks, researchers noted a 53% decrease in the inflammation marker interleukin 8 (IL-8) in the vitamin B3 group. this effect increased to 63% after 12 weeks,suggesting a reduction in lung inflammation.
The study also revealed that COPD patients frequently enough have lower levels of NAD in their blood, a molecule linked to accelerated aging. Vitamin B3 treatment increased NAD levels, potentially delaying cellular aging. Scheibye-knudsen noted that NAD loss is also seen after DNA damage,such as that associated with smoking,suggesting its potential influence on the aging process.
Scheibye-Knudsen cautioned against drawing premature conclusions about the role of NAD in aging, emphasizing the need for further research to fully understand its implications.
What’s next
Researchers plan to conduct larger studies to validate these findings and determine the long-term effects of nicotinamide riboside as a potential treatment for COPD. The goal is to develop effective treatment options for this widespread and debilitating disease.